343268-69-9

Basic information

• Product Name: Pyridine, 2-chloro-4,5-dimethyl- (9CI)
• Synonyms: Pyridine, 2-chloro-4,5-dimethyl- (9CI);2-Chloro-4,5-diMethylpyridine
• CAS NO: 343268-69-9
• Molecular Formula: C₇H₈ClN
• Molecular Weight: 141.59812
• Product Categories: PYRIDINE;Aromatics, Heterocycles, Intermediates
• Mol File: 343268-69-9.mol

Chemical Properties

• Boiling Point: 229.033°C at 760 mmHg
• Flash Point: 114.283°C
• Appearance: /
• Density: 1.114g/cm³
• Vapor Pressure: 0.107mmHg at 25°C
• Refractive Index: 1.524
• PKA: 1.34±0.10(Predicted)
• CAS DataBase Reference: Pyridine, 2-chloro-4,5-dimethyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 2-chloro-4,5-dimethyl- (9CI)(343268-69-9)
• EPA Substance Registry System: Pyridine, 2-chloro-4,5-dimethyl- (9CI)(343268-69-9)

Safety Data

• Hazardous Substances Data: 343268-69-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Pyridine, 2-chloro-4,5-dimethyl(9CI) is used as a key intermediate compound in the synthesis of MCH (melanin-concentrating hormone) receptor antagonists. These antagonists play a significant role in the development of medications targeting various central nervous system disorders, such as sleep-wake regulation, stress response, and feeding behavior. Pyridine, 2-chloro-4,5-dimethyl(9CI)'s structural features enable it to interact with MCH receptors, modulating their activity and providing therapeutic benefits.

InChI:InChI=1/C7H8ClN/c1-5-3-7(8)9-4-6(5)2/h3-4H,1-2H3

Upstream product

• 1796-86-7 3,4-dimethylpyridine 1-oxide 
• 583-58-4 3,4-Lutidin 

Relevant articles and documents

PYRIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS FOR TREATING DISEASES RELATED TO MCH RECEPTOR

The present invention encompasses novel substituted pyridine compounds of Formula (I), which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

Side-chain retention during lithiation of 4-picoline and 3,4-lutidine: Easy access to molecular diversity in pyridine series

The first direct ring-selective lithiation of 4-picoline and 3,4-lutidine has been achieved through the use of BuLi/LiDMAE aggregates to prevent the usual side-chain metallation. Several functionalities have been introduced at the C-2, C-6 and C-5 positions by ring-selective sequential lithiation, opening a simple and fast route to polysubstituted pyridine building blocks. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003.